共查询到20条相似文献,搜索用时 31 毫秒
1.
Altered bone mineral metabolism in patients with osteoarthritis 总被引:1,自引:0,他引:1
OBJECTIVE: Investigation of the relationship between osteoarthritis (OA) and mineral density, and determination of any alteration in bone mineral, metabolism as assessed by biochemical markers of bone resorption and formation. METHODS: Forty females and 20 males were included in the study. Spinal OA as well as knee OA were defined from radiographs and graded according to Lane et al.'s and Spector et al.'s scoring systems. Bone mineral density (BMD) of the lumbar spine was measured by osteo CT. Bone turnover rates were estimated by measuring biochemical markers of bone resorption (urinary deoxypyridinoline) and bone formation (bone-specific alkaline phosphatase). Forty females and 20 males of the same age were studied as a control group. RESULTS: BMD was greater in women with spinal OA as compared to controls (P < 0.05). Also, males with OA had a non-significantly higher BMD than controls. The bone resorption markers were higher than normal values. However, they were lower than the control group. Similarly, the bone formation markers were lower as compared to the control group. CONCLUSION: Spinal OA is associated with higher BMD. This protective effect of spinal OA against osteoporosis may be mediated through decreased rate of bone turnover. 相似文献
2.
Jesper Johannesen Julie Briody Mary McQuade David G. Little Christopher T. Cowell Craig F. Munns 《BONE》2009,45(5):898-902
Background: Intravenous bisphosphonate therapy is associated with preservation of femoral head sphericity and congruence in 77% of children with traumatic avascular necrosis. The aim was to describe the systemic effects of intravenous zoledronic acid (ZA) on bone and mineral metabolism in otherwise normal children and adolescents with femoral head AVN.Material and methods: 37 children (age 10.8 ± 2.76 years) diagnosed with avascular necrosis AVN (Slipped Capital Femoral Epiphysis (SCFE), N = 20 or Legg–Calve–Perthes disease (LCPD), N = 17) were treated with at least 12 months of ZA. Bone mineral density (BMD) by DXA, bone morphometry and mineral homeostasis were evaluated at baseline, 6, 12 and 18 months. Data was retrieved retrospectively.Results: All children maintained height SD during treatment. BMI SD increased in the SCFE subgroup during the first 12 month period. Bone age increased appropriately. Age adjusted total body BMD, lumbar spine BMD and lean tissue mass adjusted bone mineral content (BMC) Z-scores increased significantly over the 18 months of treatment. The LS.BMD increase was greater in LCPD than in SCFE leading to more individuals with LCPD having a LS.BMD(age) Z-score over 2 SD at 12 months follow-up. Biochemical markers of bone turnover were decreased and PTH increased during the first 12 months of treatment and bone modeling was reduced. All markers stabilised over the next 6 months. There were no incidences of fracture, spondylolisthesis or osteonecrosis of the jaw.Conclusion: We here report that ZA in otherwise healthy children with femoral head AVN increases BMD – most pronounced in the LCPD group – and reduces bone modeling and turnover. Further efficacy and safety data are required before this therapy can be widely recommended. 相似文献
3.
John A Eisman Henry G Bone David J Hosking Michael R McClung Ian R Reid Rene Rizzoli Heinrich Resch Nadia Verbruggen Carolyn M Hustad Carolyn DaSilva Romana Petrovic Arthur C Santora B Avery Ince Antonio Lombardi 《Journal of bone and mineral research》2011,26(2):242-251
The selective cathepsin K inhibitor odanacatib (ODN) progressively increased bone mineral density (BMD) and decreased bone‐resorption markers during 2 years of treatment in postmenopausal women with low BMD. A 1‐year extension study further assessed ODN efficacy and safety and the effects of discontinuing therapy. In the base study, postmenopausal women with BMD T‐scores between ?2.0 and ?3.5 at the lumbar spine or femur received placebo or ODN 3, 10, 25, or 50 mg weekly. After 2 years, patients (n = 189) were rerandomized to ODN 50 mg weekly or placebo for an additional year. Endpoints included BMD at the lumbar spine (primary), total hip, and hip subregions; levels of bone turnover markers; and safety assessments. Continued treatment with 50 mg of ODN for 3 years produced significant increases from baseline and from year 2 in BMD at the spine (7.9% and 2.3%) and total hip (5.8% and 2.4%). Urine cross‐linked N‐telopeptide of type I collagen (NTx) remained suppressed at year 3 (?50.5%), but bone‐specific alkaline phosphatase (BSAP) was relatively unchanged from baseline. Treatment discontinuation resulted in bone loss at all sites, but BMD remained at or above baseline. After ODN discontinuation at month 24, bone turnover markers increased transiently above baseline, but this increase largely resolved by month 36. There were similar overall adverse‐event rates in both treatment groups. It is concluded that 3 years of ODN treatment resulted in progressive increases in BMD and was generally well tolerated. Bone‐resorption markers remained suppressed, whereas bone‐formation markers returned to near baseline. ODN effects were reversible: bone resorption increased transiently and BMD decreased following treatment discontinuation. © 2011 American Society for Bone and Mineral Research. 相似文献
4.
Rgis Levasseur Jean-Pierre Sabatier Cline Potrel-Burgot Bertrand Lecoq Christian Creveuil Christian Marcelli 《Revue du Rhumatisme》2003,70(12):1100
Sympathetic innervation has been demonstrated in bone. Adrenergic stimulation is one of the transmitters of bone loss by uncoupling between decreased bone formation and increased bone resorption.Objective. – By using a non specific antagonist of β-adrenergic pathway (propranolol per os), we hypothesized that we could rescue the uncoupling induced mechanical unloading bone loss in the rat model of tail-suspension.Materials and methods. – Twenty-two female rats Wistar, 12 week-old, have been divided into three groups: eight tail-suspended rats (SR), six tail-suspended rats treated by propranolol (SRP) and eight non suspended rats (NSR) during 30 days. Bone mineral density (BMD, g/cm2) has been measured by DXA (Hologic QDR-4500A) at D0 and D30 of the study, in the distal femoral metaphysis (DFM), the femoral diaphysis (FD), the whole body (WB, g) and body composition.Results. – Between D0 and D30, in DFM a significant variation in BMD is observed between NSR and SR (% BMD change: NSR +15.6 ± 3.1% vs. SR –1.0 ± 1.4%, P < 0.0001) and BMD rescue in SRP group (% BMD change SRP +5.3 ± 1.5% vs. SR –1.0 ± 1.4%, P = 0.03). In FD, gain of BMD is significant in NSR compared to SR (+17.5 ± 1.5% vs. +8.2 ± 2.8%, P = 0.007), and to SRP (+17.5 ± 1.5% vs + 10.1 ± 2.4%, P = 0.046). Gain in SRP group is not significant compared to SR group (P = 0.6). In WB SRP gain more BMD than NSR (+14.0 ± 1.8% vs. +5.4 ± 0.7%, P = 0.0002) and than SR (+14.0 ± 1.8% vs. +7.8 ± 1.4%, P = 0.0043). There is no difference between NSR and SR groups (P = 0.19).Conclusion. – We demonstrate that β-adrenergic pathway of sympathetic nervous system is a major transmitter pathway of mechanical loading in rat bone. A specific study is necessary to analyse a possible systemic effect of propranolol in rat bone. Propranolol could be used to prevent induced mechanical unloading bone loss as weightlessness. 相似文献
5.
Hector F DeLuca Wendy Bedale Neil Binkley J Chris Gallagher Michael Bolognese Munro Peacock John Aloia Margaret Clagett‐Dame Lori Plum 《Journal of bone and mineral research》2011,26(3):538-545
Most osteoporosis drugs act by inhibiting bone resorption. A need exists for osteoporosis therapies that stimulate new bone formation. 2‐Methylene‐19‐nor‐(20S)‐1α,25‐dihydroxyvitamin D3 (2MD) is a vitamin D analogue that potently stimulates bone formation activity in vitro and in the ovariectomized rat model. In this randomized, double‐blind, placebo‐controlled study of osteopenic women, the effect of daily oral treatment with 2MD on bone mineral density (BMD), serum markers of bone turnover, and safety were assessed over 1 year. Volunteers were randomly assigned to three treatment groups: placebo (n = 50), 220 ng of 2MD (n = 54), and 440 ng of 2MD (n = 53). In general, 2MD was well tolerated. Although 2MD caused a marked increase in markers of bone formation, it did not significantly increase BMD. Since 2MD also shows marked activity on bone resorption (as revealed by dose‐dependent increases in serum C‐telopeptide cross‐links of type I collagen in this study), 2MD likely stimulated both bone formation and bone resorption, thereby increasing bone remodeling. © 2011 American Society for Bone and Mineral Research. 相似文献
6.
Bone loss occurs close to a fracture and is associated with increased bone turnover. Fracture healing itself results in increased
markers of bone turnover. But the exact patterns of these changes after different fractures are unclear. We aimed to investigate
the changes in bone density and biochemical markers following distal forearm fracture. Twenty women (mean age 63 years) were
recruited following fracture of the distal radius and ulna. Bone mineral density (BMD) of the hand and forearm were measured
by dual-energy X-ray absorptiometry (DXA) and quantitative ultrasound (QUS) of the fingers was measured at 0, 6, 12, 26 and
52 weeks after fracture. Serum and urine samples were collected at 0, 3 and 7 days and at 2, 4, 6, 12, 26 and 52 weeks after
fracture to measure markers of bone turnover. For bone formation we measured: bone alkaline phosphatase (iBAP), osteocalcin
(Oc), procollagen type I N-terminal propeptide (PINP); and for bone resorption: tartrate-resistant acid phosphatase (TRAcP),
free deoxypyridinoline (iFDpd), N-telopeptides of type I collagen (NTx). We used the nonfractured limb to calculate values
for baseline BMD and amplitude-dependent speed of sound (AD-SoS). There was a decrease in BMD at the hand and in AD-SoS of
the fingers after forearm fracture (p<0.001). This bone loss was maximal for BMD by 6 weeks at 9% (p<0.001) and remained decreased at 52 weeks. AD-SoS decreased at 12 weeks by 3% (p<0.01) and recovered completely by 52 weeks. Bone formation markers increased between 2 and 4 weeks by 13–52% (p<0.001), and were still elevated at 52 weeks. Bone resorption markers increased between 2 and 6 weeks by 18–35% and returned
to baseline at 52 weeks (TRAcP remained elevated). We conclude that BMD decreased distal and immediately proximal to the fracture
line when measured with DXA and QUS. Bone loss after distal forearm fracture did not recover by 52 weeks and most bone turnover
markers did not return to baseline.
Received: 27 January 1999 / Accepted: 19 April 1999 相似文献
7.
STUDY DESIGN:A prospective observational study.OBJECTIVE:To evaluate bone mineral density (BMD) and biochemical markers of bone turnover in spinal cord-lesioned females in the early postmenopausal period.SETTING:Clinic for Spinal Cord Injuries, H:S Rigshospitalet, Denmark.MATERIAL:In all, 18 early postmenopausal females with spinal cord lesions (SCL) of more than 2 years duration were recruited. In total, 11 completed the study.METHODS:Using dual energy X-ray absorption, BMD of the lumbar spine, femoral neck, trochanter and proximal tibia was measured every 6 months for 30 months. Biochemical markers of bone turnover in blood and urine were collected at the same time points.RESULTS:A significant increase in markers of bone formation in the blood was found and markers of bone resorption in urine tended to increase. BMD values changed insignificantly but for all regions decreased, except the lumbar spine.CONCLUSION:An accelerated bone turnover occurs in early postmenopausal SCL females. At the same time, we showed an insignificant decrease in BMD data from the lower extremity. 相似文献
8.
Changes in Bone Mass and Bone Turnover Following Ankle Fracture 总被引:6,自引:0,他引:6
Bone loss and increased bone turnover are recognized local changes after a fracture, but the exact patterns of these changes
after different fractures are unclear. We aimed to investigate the changes in bone density and biochemical markers following
ankle fracture. Fourteen subjects (7 postmenopausal women and 7 men, mean age 63 years) were recruited following fracture
of the distal tibia and fibula. Bone mineral density (BMD) of the ankle and proximal femur were measured by dual-energy X-ray
absorptiometry (DXA) and quantitative ultrasound (QUS) of the calcaneus at 0, 6, 12, 26 and 52 weeks after fracture. Serum
and urine samples were collected at 0, 3 and 7 days and at 2, 4, 6, 12, 26 and 52 weeks after fracture to measure markers
of bone turnover. For bone formation we measured: bone alkaline phosphatase (iBAP), osteocalcin (Oc), procollagen type I N-terminal
propeptide (PINP); and for bone resorption: tartrate-resistant acid phosphatase (TRAcP), deoxypyridinoline (iFDpd), N-telopeptides
of type I collagen (NTx). We used the nonfractured limb to calculate values for baseline BMD and QUS. There was a significant
decrease in BMD at the ultradistal ankle (p<0.001), the trochanteric region of the hip (p<0.01) and QUS of the heel after ankle fracture. This bone loss was maximal for ultradistal ankle BMD by 6 weeks at 13% (p<0.001) and for the trochanter by 26 weeks at 3% (p<0.01). The ankle BMD returned to baseline at 52 weeks but the trochanter BMD did not. Velocity of sound (VOS) decreased at
6 weeks by 2% (p<0.01) and broadband ultrasound attenuation (BUA) by 15% (p<0.01). VOS recovered completely by 52 weeks, but BUA did not return to baseline. Bone formation markers increased significantly
between 1 and 4 weeks by 11–78% (p<0.01), and iBAP returned to baseline at 52 weeks but PINP and Oc remained elevated. Bone resorption markers did not increase
and NTx was decreased at 52 weeks. We conclude that BMD decreased distal and immediately proximal to the fracture line when
measured with DXA and QUS. Ankle BMD and heel VOS recovered at 52 weeks (trochanteric BMD and heel BUA did not) and the bone
turnover markers returned toward baseline.
Received: 27 January 1999 / Accepted: 19 April 1999 相似文献
9.
We investigated the role of vitamin D and of parathyroid hormone (PTH) in the regulation of bone mineral density (BMD), tone dimensions and seasonal variation of bone turnover in 881 men aged 19–85 years. Bone mineral content (BMC) and BMD of the lumbar spine, hip and whole body were measured with HOLOGIC 1000W and those of distal forearm with an OSTEOMETER DTX 100 device. Bone formation was evaluated using osteocalcin, bone alkaline phosphatase and N-terminal extension propeptide of type I collagen (PINP). Bone resorption was evaluated by 24-hour excretion of deoxypyridinoline and of C-terminal telopeptide of collagen type I. In young men (<55 yrs) PTH level decreased with age (r = –0.18, P < 0.005) whereas 25-hydroxyvitamin D (25OHD) concentration was stable. In older men (>55 years) 25OHD decreased whereas PTH increased with age (r = –0.27 and r = 0.21, P = 0.0001). In young men, 25OHD level varied with season but not PTH, biochemical markers of bone turnover nor BMD. In young men, 25OHD, but not PTH, was a significant determinant of BMC, cortical thickness and of biomechanical properties of the femoral neck. Biochemical bone markers and BMD were not correlated with PTH nor with 25OHD. In elderly men, winter levels of 25OHD were lowest whereas those of PTH, bone resorption markers and PINP were highest. After adjustment for age, body weight and season, biochemical markers of bone turnover were correlated with PTH. In elderly men, 25OHD and PTH were significant determinants of BMC, cortical thickness and of biomechanical parameters of the femoral neck. Men with vertebral deformities had lower concentrations of 25OHD, higher PTH levels and slightly elevated urinary excretion of biochemical markers of bone resorption compared with men without vertebral deformities. In conclusion, in young men, 25OHD discloses a seasonal variability in contrast to PTH and biochemical bone markers. In this group, 25OHD is a significant determinant of BMC and BMD but not of bone size. In elderly men, seasonal variation of 25OHD and PTH concentrations result in seasonal variation of bone resorption. In this group, both 25OHD and PTH are determinants of BMC and cortical thickness of the femoral neck and, consequently, of its mechanical parameters. 相似文献
10.
Ethnic and Gender Differences in Bone Mineral Density and Bone Turnover in Young Adults: Effect of Bone Size 总被引:6,自引:3,他引:3
Generally, the incidence of osteoporotic fracture is lower in black populations and in men. These effects of ethnicity and
gender may result from differences in peak bone mineral density (PBMD) and bone turnover (BT), which in turn are affected
by bone size. Therefore, the aims of this study were to examine the effects of ethnicity and gender on bone mineral density
(BMD) and BT in young African-Caribbean and Caucasian adults, and to adjust for the effect of bone size on BMD and BT. BMD
was measured at the lumbar spine, L2–L4 (LS), total body (TB) and femoral neck (FN) by dual-energy X-ray absorptiometry in
44 blacks (16 men, 28 women) and 59 whites (28 men, 31 women) ages 20–37 years. We measured serum bone-specific alkaline phosphatase
(BAP) and serum osteocalcin (OC) as markers of bone formation and urinary immunoreactive free deoxypyridinoline (ifDpd) and
crosslinked N-telopeptide of type I collagen (NTx) as markers of bone resorption. To adjust the data for any differences in
bone size, we calculated: (a) bone mineral apparent density (BMAD), an estimated volumetric bone density which attempts to
normalize BMD measurements for bone size; and (b) bone resorption markers as a ratio to total body bone mineral content (TB
BMC). Two-way analysis of variance was used to compare the effects of race and gender, and to test for any interaction between
these two factors. Blacks had higher BMD compared with whites at the TB (p<0.001), LS (p= 0.0001) and FN (p= 0.0005). This increase remained significant at the LS only after calculating BMAD. Men had higher BMD at all sites (except
at the LS). This increase was no longer significant at the FN after calculating BMAD, and LS BMAD was actually greater in
women (p<0.0001). Blacks and whites had similar concentrations of turnover markers, but men had higher bone turnover markers than
women (BAP, p<0.0001; OC, p= 0.002; ifDpd, p= 0.03; NTx, p<0.0001). This increase in bone resorption markers was no longer significant after adjusting for TB BMC (except for NTx in
whites). We conclude that the skeletal advantage in blacks during young adulthood is not explained by bone size. However,
it seems probable that bone size effects partially explain gender differences in BMD and bone turnover.
Received: 2 February 1999 / Accepted: 2 December 1999 相似文献
11.
High Bone Turnover is Associated with Low Bone Mass and Spinal Fracture in Postmenopausal Women 总被引:4,自引:0,他引:4
P. Ravn M. Rix H. Andreassen B. Clemmesen M. Bidstrup M. Gunnes 《Calcified tissue international》1997,60(3):255-260
A group of 366 healthy, white postmenopausal women, aged 50–81 years, mean age 66 years, were selected from the screened
population of Scandinavians who were part of a multicenter study of the efficacy of tiludronate, a new bisphosphonate, in
established postmenopausal osteoporosis. Eighty-eight women had a lumbar spine bone mineral density (BMD) above 0.860 g/cm2, and 278 women had a BMD below 0.860 g/cm2. Spinal fracture was diagnosed from lateral spine X-ray studies and defined as at least 20% height reduction (wedge, compression,
or endplate fracture) in at least one vertebra (T4–L4). Bone resorption was assessed by measurement of the urinary excretion
of type I collagen degradation products by the CrossLaps™ enzyme-linked immunoassay (ELISA). Bone formation was assessed by
ELISA measurement of the N-terminal-mid-fragment as well as the intact serum osteocalcin (OCN-MID), thus omitting the influence of the instability of osteocalcin caused by the labile 6 amino acid C-terminal sequence. The
women were divided into groups with high or low bone turnover according to the concentrations of urinary CrossLaps™ or OCN-MID. Women in the quartiles with the highest concentrations of CrossLaps [519 ± 119 μg/mmol (SD)] or OCN-MID [44.6 ± 7.5 ng/ml (SD)] had 10–16% lower spinal BMD compared with women in the lowest quartiles (CrossLaps 170 ± 48 μg/mmol
(SD), and OCN-MID [22.1 ± 3.0 ng/ml (SD)] (P < 0.0004). The prevalences of spinal fracture were 25 to 29% in the lowest quartiles, whereas the prevalences in the highest
quartiles were almost double—53–54% (P < 0.006). If the women were subgrouped according to spinal BMD and prevalence of spinal fracture, corresponding results were
found. Women with a BMD less than 0.860 g/cm2, without or with spinal fracture (n = 136 and n = 142), had 36–43% higher concentration of CrossLaps (P= 0.0001) and 11–15% higher concentration of OCN-MID (P < 0.02), as compared with women with a BMD above 0.860 g/cm2 and no spinal fracture (n = 84). In conclusion, the results indicate a strong association among high bone turnover, low bone
mass, and prevalence of spinal fracture, which supports the theory that high bone turnover is a risk factor for spinal fracture
and osteoporosis.
Received: 29 February 1996 / Accepted: 9 August 1996 相似文献
12.
A Randomized,Double‐Blind Phase 2 Clinical Trial of Blosozumab,a Sclerostin Antibody,in Postmenopausal Women with Low Bone Mineral Density
下载免费PDF全文
![点击此处可从《Journal of bone and mineral research》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Robert R. Recker Charles T. Benson Toshio Matsumoto Michael A. Bolognese Deborah A. Robins Jahangir Alam Alan Y Chiang Leijun Hu John H Krege Hideaki Sowa Bruce H. Mitlak Stephen L. Myers 《Journal of bone and mineral research》2015,30(2):216-224
Sclerostin, a SOST protein secreted by osteocytes, negatively regulates formation of mineralized bone matrix and bone mass. We report the results of a randomized, double‐blind, placebo‐controlled multicenter phase 2 clinical trial of blosozumab, a humanized monoclonal antibody targeted against sclerostin, in postmenopausal women with low bone mineral density (BMD). Postmenopausal women with a lumbar spine T‐score –2.0 to –3.5, inclusive, were randomized to subcutaneous blosozumab 180 mg every 4 weeks (Q4W), 180 mg every 2 weeks (Q2W), 270 mg Q2W, or matching placebo for 1 year, with calcium and vitamin D. Serial measurements of spine and hip BMD and biochemical markers of bone turnover were performed. Overall, 120 women were enrolled in the study (mean age 65.8 years, mean lumbar spine T‐score –2.8). Blosozumab treatment resulted in statistically significant dose‐related increases in spine, femoral neck, and total hip BMD as compared with placebo. In the highest dose group, BMD increases from baseline reached 17.7% at the spine, and 6.2% at the total hip. Biochemical markers of bone formation increased rapidly during blosozumab treatment, and trended toward pretreatment levels by study end. However, bone specific alkaline phosphatase remained higher than placebo at study end in the highest‐dose group. CTx, a biochemical marker of bone resorption, decreased early in blosozumab treatment to a concentration less than that of the placebo group by 2 weeks, and remained reduced throughout blosozumab treatment. Mild injection site reactions were reported more frequently with blosozumab than placebo. In conclusion, treatment of postmenopausal women with an antibody targeted against sclerostin resulted in substantial increases in spine and hip BMD. These results support further study of blosozumab as a potential anabolic therapy for osteoporosis. © 2014 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research (ASBMR) 相似文献
13.
Masaaki Takahashi Kenichi Naitou Tsuyoshi Ohishi Akira Nagano 《Journal of clinical densitometry》2003,6(3):211-218
Bone density and the biochemical markers of bone turnover were compared between 26 hip-fracture patients and 41 vertebral-fracture patients after age adjustment to investigate whether or not type of osteoporosis differs between hip fracture and vertebral fracture. C-Terminal propepides of type I collagen (PIPC) was lower in hip fracture than vertebral fracture. The other bone formation markers (bone-specific alkaline phosphatase [ALP], osteocalcin) tended to be lower, and bone resorption markers (deoxypyridinoline, C-telopeptide crosslinking of type I collagen [CTX] tended to be higher in hip fracture compared to vertebral fracture. Mean of Z-scores of spine bone mineral density (BMD) in hip fracture and vertebral fracture were -0.461 and -0.919, respectively. Mean of Z-scores of femoral neck BMD in hip fracture and vertebral fracture were -0.994 and -0.361, respectively. All Z-scores were negative values, which means reduction of BMD compared to decade-matched controls. Z-scores of bone formation markers, such as bone-specific ALP, osteocalcin, and PIPC, were positive values in vertebral fracture, which means an increase against decade-matched controls, whereas those were negative values in hip fracture. Z-scores of bone resorption markers, such as deoxypyridinoline and CTX, were greater in hip fracture than in vertebral fracture. To express bone balance between formation and resorption in hip fracture and vertebral fracture, we calculated an uncoupling status index (USI) by the values of biochemical markers. USI of hip fracture showed a great negative value (-1.29), which indicates excess of bone resorption over formation, whereas that of vertebral fracture showed a small positive value (0.23). In conclusion, bone formation markers increase in vertebral fractures, but decrease in hip fracture. Bone resorption markers increase in both fracture, but greater increase in hip fracture. 相似文献
14.
The clinical significance of serum osteocalcin and N-terminal propeptide of type I collagen in predialysis patients with chronic renal failure 总被引:2,自引:0,他引:2
Takao Tsuchida Eiji Ishimura Takami Miki Naoki Matsumoto Hiroshi Naka Shuichi Jono Masaaki Inaba Yoshiki Nishizawa 《Osteoporosis international》2005,16(2):172-179
Several new serum markers for bone metabolism have recently become available and are being applied to clinical practice. Their clinical usefulness in predialysis patients with chronic renal failure (CRF), however, has not yet been determined. Serum levels of three bone formation markers—bone alkaline phosphatase (BAP), osteocalcin (OC), and N-terminal propeptide of type I collagen (PINP)—and three bone resorption markers—type I collagen cross-linked N-telopeptide (NTx), deoxypyridinoline (DPD), and pyridinoline (PYD)—were measured simultaneously in 85 predialysis CRF patients (serum creatinine 3.5 ± 1.9 mg/dl, 61.0 ± 10.9 years old, 54 males and 31 females, 36 diabetics and 49 nondiabetics) to examine the relationships between these markers and bone mineral density (BMD) of the distal radius, as measured by peripheral quantitative computed tomography (pQCT). Trabecular BMD, which is strongly affected by bone metabolism, was significantly negatively correlated with each of the bone formation markers (r=–0.341, p=0.0016, for OC; r=–0.314, p=0.0036, for PINP; r=–0.238, p=0.0315, for BAP), but there was no significant correlation between BMD and any of the bone resorption markers. In multivariate regression analyses (adjusted by age, sex, presence of diabetes, glomerular filtration rate, intact parathyroid hormone, calcium, phosphate, and 1,25-dihydroxyvitamin D), OC and PINP were significantly associated with a decrease in BMD, but BAP was not. In conclusion, we demonstrated that in predialysis CRF patients, BMD of the distal radius, particularly of trabecular bone, is associated with serum OC and PINP levels. OC and PINP are suggested to be possible parameters for the clinical evaluation of the effect of bone metabolism on BMD. 相似文献
15.
Nakata Y Ohkawara K Lee DJ Okura T Tanaka K 《Journal of bone and mineral metabolism》2008,26(2):172-177
Bone loss accompanies a diet-induced weight loss and could be prevented with a combination of exercises. This study was conducted
to examine the effects of additional resistance training during diet-induced weight loss on whole-body and selected regional
bone mineral density (BMD). The participants of a 14-week weight-loss study were 42 overweight premenopausal Japanese women
who were randomly placed in either a diet-only group (D; n = 21) or a diet plus resistance training group (DR; n = 21). Whole-body BMD and body composition, lumbar spine BMD, and 1/3 radial BMD were measured by dual-energy X-ray absorptiometry
before and after the intervention. Bone formation and resorption markers were also measured. Thirty-five participants (83%)
completed the study. Individuals in groups D (n = 17) and DR (n = 18) lost 6.2 ± 3.5 kg and 8.6 ± 3.6 kg body weight, respectively. Reductions in percentage fat mass and fat mass in group
DR were significantly greater than in group D; lean mass decreased significantly in both groups. The effect of time on whole-body
BMD was significant (−0.3%); however, whole-body bone mineral content, lumbar spine BMD, and 1/3 radial BMD remained unchanged.
There were no significant timeby-group interactions in the whole-body and regional BMD and bone markers. These results suggest
that additional resistance training during weight loss has no effect on BMD in overweight premenopausal Japanese women. Further
long-term studies with large numbers of subjects are needed. 相似文献
16.
Jawl-Shan Hwang Miaw-Jene Liou Cheng Ho Jen-Der Lin Yu-Yao Huang Chao-Jan Wang Keh-Sung Tsai Jung-Fu Chen 《Journal of bone and mineral metabolism》2010,28(3):328-333
The aim of this study was to evaluate the efficacy, safety, and tolerability of weekly alendronate administration on male
osteoporosis in Taiwan. This 6-month, randomized, open-label controlled trial enrolled 46 men with osteoporosis who were randomized
to either 70 mg alendronate once weekly (n = 23) or control (n = 23). Bone mineral density (BMD) of lumbar spine and hip and biochemical bone turnover markers were measured; adverse events
and tolerability were assessed. Subjects treated with alendronate showed a significant increase in BMD of 5.5% (vs. 2% in
control group) at the lumbar spine and 2.7% (vs. 0.7%) at the femoral neck (P < 0.05) at 6 months, respectively. There were also significant decreases in serum level of bone formation marker (bone-specific
alkaline phosphatase) and urinary excretion of bone resorption marker (deoxypyridinoline) at 3 and 6 months. Thus, alendronate
showed anti-osteoporotic effects by increasing BMD and decreasing the concentrations of bone markers. The adverse events were
mild and showed no significant difference between the two groups on safety assessments. 相似文献
17.
Iwasaki Y Yamato H Murayama H Sato M Takahashi T Ezawa I Kurokawa K Fukagawa M 《Journal of bone and mineral metabolism》2003,21(3):154-160
Bisphosphonate is a potent inhibitor of bone resorption, which results in the increase of bone volume. However, bisphosphonate
treatment may lead to extremely low bone turnover and abnormal bone microstructure. In this study, we examined whether the
combination of bisphosphonate with vitamin K2 treatment may have beneficial effects on bone turnover and trabecular microstructure as well as on bone volume loss by using
tail-suspension model rats. In these model rats, bone mineral density (BMD) decreased with histological evidence of enhanced
bone resorption and suppressed bone formation. By bisphosphonate treatment, BMD was increased compared with that of tail-suspended
rats. Osteoclast surface per bone surface (Oc.S/BS) and number of osteoclasts per bone perimeter (N.Oc/B.Pm) were reduced
and mineral apposition rate (MAR) decreased, suggesting extreme suppression of bone turnover. However, trabecular structure
examined by microfocus CT was apparently abnormal. By contrast, combination of bisphosphonate with vitamin K2 leads to further increase of bone volume. MAR and BFR as well as Oc.S/BS and N.Oc/B.Pm were increased compared with those
of the bisphosphonate-treated group. However, abnormal structure of trabeculae in secondary spongiosa was not completely ameliorated.
These data suggested that concomitant use of vitamin K2 with bisphosphonate excessively ameliorates too much suppression of bone turnover while more efficiently preventing bone
volume loss.
Received: January 30, 2002 / Accepted: November 6, 2002
RID="*"
ID="*" Present address: Department of Health Sciences, Oita University of Nursing and Health Sciences, Oita, Japan
Acknowledgments. This work was supported in part by a Special Grant for Medical Research from Ministry of Post and Telecommunications, Japan
(to M.F.), a grant in aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology
(#13671115 to M.F.), and by a grant from the Research Society for Metabolic Bone Disease (to M.F.). We are grateful to Miss
Sachiko Suzuki for technical assistance.
Offprint requests to: M. Fukagawa 相似文献
18.
Goemaere S Van Pottelbergh I Zmierczak H Toye K Daems M Demuynck R Myny H De Bacquer D Kaufman JM 《BONE》2001,29(3):286-291
Bone loss is accelerated in elderly men. Little is known about the pathophysiology of senile bone loss or about the role played by relative sex steroid deficiency in the determination of bone turnover in elderly men. In a population-based sample of 283 healthy, ambulatory men, aged 71-86 years, we sought to determine whether lower bone mineral density (BMD; using dual-energy X ray absorptiometry at the hip and the forearm) is associated with higher bone turnover, and we assessed the impact of sex steroid status on bone turnover. Indices of bone formation, serum osteocalcin (s-Oc), and bone-specific alkaline phosphatase (s-bAP) and indices of bone resorption, serum and urinary telopeptide of type I collagen (s-CTx and u-CTx), and urinary free deoxypyridinoline (u-Dpd) were intercorrelated (r = 0.29-0.76, p < 0.001). Bone turnover indices were negatively associated with BMD (r = -0.17 to -0.34, p < 0.01). In univariate analyses, there was a trend toward weak negative associations of bone turnover markers with serum free testosterone (FT), significant only for s-Oc and s-CTx (r = -0.16 and -0.14, p < 0.01), and with serum free estradiol (FE(2)), significant only for u-CTx and s-CTx (r = -0.18 and -0.19; p < 0.01). The lower quartile for FE(2) was associated with higher values of u-CTx (p = 0.003) and s-CTx (p < 0.001). However, in multivariate models, for the individual markers of bone turnover a negative association between estradiol (E(2)) or FE(2) and s-CTx was the only remaining (marginally) significant association (p < 0.05) for the relationship between sex steroids and any of the bone turnover indices assessed. In community-dwelling men age >70 years, bone turnover rate, as determined by biochemical markers, is a significant negative determinant of prevalent BMD. However, the findings do not support the view that relative differences in sex steroid status, as observed among healthy elderly men, have a major impact on bone turnover. 相似文献
19.
Masarachia PJ Pennypacker BL Pickarski M Scott KR Wesolowski GA Smith SY Samadfam R Goetzmann JE Scott BB Kimmel DB Duong le T 《Journal of bone and mineral research》2012,27(3):509-523
Odanacatib (ODN) is a selective and reversible inhibitor of cathepsin K (CatK) currently being developed as a once‐weekly treatment for osteoporosis. In this study, we evaluated the effects of ODN on bone turnover, bone mineral density (BMD), and bone strength in the lumbar spine of estrogen‐deficient, skeletally mature rhesus monkeys. Ovariectomized (OVX) monkeys were treated in prevention mode for 21 months with either vehicle, ODN 6 mg/kg, or ODN 30 mg/kg (p.o., q.d.) and compared with intact animals. ODN treatment persistently suppressed the bone resorption markers (urinary NTx [75% to 90%] and serum CTx [40% to 55%]) and the serum formation markers (BSAP [30% to 35%] and P1NP [60% to 70%]) versus vehicle‐treated OVX monkeys. Treatment with ODN also led to dose‐dependent increases in serum 1‐CTP and maintained estrogen deficiency–elevated Trap‐5b levels, supporting the distinct mechanism of CatK inhibition in effectively suppressing bone resorption without reducing osteoclast numbers. ODN at both doses fully prevented bone loss in lumbar vertebrae (L1 to L4) BMD in OVX animals, maintaining a level comparable to intact animals. ODN dose‐dependently increased L1 to L4 BMD by 7% in the 6 mg/kg group (p < 0.05 versus OVX‐vehicle) and 15% in the 30 mg/kg group (p < 0.05 versus OVX‐vehicle) from baseline. Treatment also trended to increase bone strength, associated with a positive and highly significant correlation (R = 0.838) between peak load and bone mineral content of the lumbar spine. Whereas ODN reduced bone turnover parameters in trabecular bone, the number of osteoclasts was either maintained or increased in the ODN‐treated groups compared with the vehicle controls. Taken together, our findings demonstrated that the long‐term treatment with ODN effectively suppressed bone turnover without reducing osteoclast number and maintained normal biomechanical properties of the spine of OVX nonhuman primates. © 2012 American Society for Bone and Mineral Research 相似文献
20.
Leah T Braun Julia Fazel Stephanie Zopp Sarina Benedix Andrea Osswald-Kopp Anna Riester German Rubinstein Max Seidensticker Felix Beuschlein Michael Drey Martin Bidlingmaier Ralf Schmidmaier Martin Reincke 《Journal of bone and mineral research》2020,35(9):1711-1717
Endogenous Cushing's syndrome (CS) is a rare cause of secondary osteoporosis. The long-term consequences for bone metabolism after successful surgical treatment remain largely unknown. We assessed bone mineral density and fracture rates in 89 patients with confirmed Cushing's syndrome at the time of diagnosis and 2 years after successful tumor resection. We determined five bone turnover markers at the time of diagnosis, 1 and 2 years postoperatively. The bone turnover markers osteocalcin, intact procollagen-IN-propeptide (PINP), alkaline bone phosphatase, CTX-I, and TrAcP 5b were measured in plasma or serum by chemiluminescent immunoassays. For comparison, 71 sex-, age-, and body mass index (BMI)-matched patients in whom Cushing's syndrome had been excluded were studied. None of the patients received specific osteoanabolic treatment. At time of diagnosis, 69% of the patients had low bone mass (mean T-score = −1.4 ± 1.1). Two years after successful surgery, the T-score had improved in 78% of patients (mean T-score 2 years postoperatively −1.0 ± 0.9). The bone formation markers osteocalcin and intact PINP were significantly decreased at time of diagnosis (p ≤ 0.001 and p = 0.03, respectively), and the bone resorption marker CTX-I and TrAcP 5b increased. Postoperatively, the bone formation markers showed a three- to fourfold increase 1 year postoperatively, with a moderate decline thereafter. The bone resorption markers showed a similar but less pronounced course. This study shows that the phase immediately after surgical remission from endogenous CS is characterized by a high rate of bone turnover resulting in a striking net increase in bone mineral density in the majority of patients. © 2020 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research. 相似文献